Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Factors related to response to intermittent treatment of mycobacterium avium complex lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 557s Year: 2006
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Long-term survival of patients with mycobacterium avium- intracellulare complex pulmonary disease (MAC-PD) Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016 Year: 2017
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Mycobacterium avium complex infection: phenotypes and outcomesSource: Eur Respir J, 50 (3) 1701380; 10.1183/13993003.01380-2017 Year: 2017
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
A case of familial pulmonary Mycobacterium avium complex disease – experience in Japan Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Insufficient serum L-ficolin is associated with the disease progression in pulmonary Mycobacterium avium complex disease Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Antibody testing for Mycobacterium avium complex infection in cystic fibrosis patients Source: International Congress 2018 – Cystic fibrosis: microbiological aspects and new treatments Year: 2018